| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/21/2013 | US8445272 Method of stimulating NKT with 6″-amino-6″-deoxygalactosylceramides |
| 05/21/2013 | US8445268 Her-2/neu DNA vaccine having anti-cancer activity |
| 05/21/2013 | US8445237 RNA interference mediating small RNA molecules |
| 05/21/2013 | US8445041 Dehydrated castor oil as an animal feed supplement |
| 05/21/2013 | US8445032 Melt-blended protein composition |
| 05/21/2013 | US8445030 Persistent and fast acting antiseptics and disinfectants based on calcium fluoride |
| 05/21/2013 | US8445026 Selenium nanoparticles with improved biological effects |
| 05/21/2013 | US8445015 Extended-release formulation for reducing the frequency of urination and method of use thereof |
| 05/21/2013 | US8445014 Ion binding compositions |
| 05/21/2013 | US8445013 Stable pharmaceutical composition and methods of using same |
| 05/21/2013 | US8445011 Delayed-release formulation for reducing the frequency of urination and method of use thereof |
| 05/21/2013 | US8445010 Abuse potential reduction in abusable substance dosage form |
| 05/21/2013 | US8445005 Antiwrinkle agent, lipolysis promoter, external composition for skin and food and beverage composition |
| 05/21/2013 | US8444988 Cancer treatment method |
| 05/21/2013 | US8444961 RNA virus infection inhibitor, method for inhibition of infection by RNA virus, RNA virus infection-inhibiting product, and use as RNA virus infection inhibitor |
| 05/21/2013 | US8444960 Topical administration carrier composition and therapeutic formulations comprising same |
| 05/21/2013 | CA2688641C Control of ectoparasites with mitochondrial complex 1 inhibitors |
| 05/21/2013 | CA2679452C Carbohydrate-based peritoneal dialysis fluid comprising glutamine residue |
| 05/21/2013 | CA2662580C Tyrosine kinase inhibitors containing a zinc binding moiety |
| 05/21/2013 | CA2583783C Complex containing mequitazine, a cyclodextrin and an interaction agent |
| 05/21/2013 | CA2583397C Therapeutic agents targeting the ncca-atp channel and methods of use thereof |
| 05/21/2013 | CA2580189C Sirna-mediated gene silencing of alpha synuclein |
| 05/21/2013 | CA2579533C Drug delivery from embolic agents |
| 05/21/2013 | CA2577258C Biotinylated hexadecasaccharides, their preparation and their use as anticoagulants and antithrombotics of heparin |
| 05/21/2013 | CA2571726C Prodrugs of hiv protease inhibitors |
| 05/21/2013 | CA2565134C Novel oral formulations of ospemifene |
| 05/21/2013 | CA2560162C Inhibitors of iap |
| 05/21/2013 | CA2559802C Method for stimulating the immune, inflammatory or neuroprotective response |
| 05/21/2013 | CA2556993C Pimecrolimus foam composition containing hexylene glycol, optionally oleyl alcohol, dimethylisosorbide and/or medium chain triglycerides |
| 05/21/2013 | CA2553805C Improved inactivated feline calicivirus vaccines |
| 05/21/2013 | CA2548918C Alpha-amino acid derivatives and use thereof as medicines |
| 05/21/2013 | CA2547934C Methods of using gamma cyclodextrin to control blood glucose and insulin secretion |
| 05/21/2013 | CA2528649C Analgesic and anti-inflammatory patch |
| 05/21/2013 | CA2518541C Gonadal function improving agents |
| 05/21/2013 | CA2481499C Use of cyclopamine in the treatment of psoriasis and other skin disorders |
| 05/21/2013 | CA2459869C A system for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer |
| 05/21/2013 | CA2454147C Inhibitor of dna methylation |
| 05/21/2013 | CA2451109C Infection control system |
| 05/21/2013 | CA2436666C Use of zwitterionic polysaccharides for the specific modulation of immune processes |
| 05/21/2013 | CA2428753C Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines |
| 05/21/2013 | CA2401821C Amino acid derivatives as hiv aspartyl protease inhibitors |
| 05/21/2013 | CA2397987C Use of at least a fatty ester for preparing a composition designed to inhibit 5 alpha reductase activity, in pharmacology, in particular dermatology, in cosmetics and as food additive |
| 05/21/2013 | CA2396688C Glycosidase inhibitors and methods of synthesizing same |
| 05/21/2013 | CA2349203C Dispersible phospholipid stabilized microparticles |
| 05/18/2013 | CA2795893A1 Controlled release formulations of tolterodine and process of manufacturing |
| 05/18/2013 | CA2758657A1 Controlled release formulations of tolterodine and process of manufacturing |
| 05/17/2013 | CA2758556A1 Pharmaceutical composition of amphetamine mixed salts |
| 05/16/2013 | WO2013071282A1 Pkc activators and combinations thereof |
| 05/16/2013 | WO2013071281A1 Esters of dcpla and methods of treatment using the same |
| 05/16/2013 | WO2013071232A1 Compositions and methods for inhibition of tbl-1 binding to disease-associated molecules |
| 05/16/2013 | WO2013071217A1 Dihydropteridinones |
| 05/16/2013 | WO2013071214A1 Synergistic anti-cancer activity of sr16388 with anti-mitotic drugs |
| 05/16/2013 | WO2013071203A1 2,5-dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (fprl-1) receptor modulators |
| 05/16/2013 | WO2013071201A1 Substituted benzylspiroindolin-2-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
| 05/16/2013 | WO2013071177A1 Methods and compositions for inhibition of androgen receptor activity |
| 05/16/2013 | WO2013071169A1 Acc inhibitors and uses thereof |
| 05/16/2013 | WO2013071142A1 Biomarkers of response to proteasome inhibitors |
| 05/16/2013 | WO2013071106A1 Administration of a bis(thiohydrazide amide) compound for treating cancers |
| 05/16/2013 | WO2013071097A1 2,5-disubstituted-pyridyl nicotinic ligands, and methods of use thereof |
| 05/16/2013 | WO2013071094A1 Compounds useful as inhibitors of atr kinase |
| 05/16/2013 | WO2013071093A1 Pyrazine compounds useful as inhibitors of atr kinase |
| 05/16/2013 | WO2013071090A1 Compounds useful as inhibitors of atr kinase |
| 05/16/2013 | WO2013071089A1 Opioid analgesics and 3-hydroxyacetanilide for treating pain |
| 05/16/2013 | WO2013071088A1 Compounds useful as inhibitors of atr kinase |
| 05/16/2013 | WO2013071085A1 Pyrazine compounds useful as inhibitors of atr kinase |
| 05/16/2013 | WO2013071079A1 Lin28/let-7 crystal structures, purification protocols, and molecular probes suitable for screening assays and therapeutics |
| 05/16/2013 | WO2013071077A1 The use of pan-ppar agonists for prevention and treatment of huntington's disease and tauopathies |
| 05/16/2013 | WO2013071068A2 Treatment of hematologic malignancies with an anti-cxcr4 antibody |
| 05/16/2013 | WO2013071061A1 Compositions and methods for increasing stress resilience |
| 05/16/2013 | WO2013071056A2 Combination drug therapy for the treatment of solid tumors |
| 05/16/2013 | WO2013071027A1 Macrocyclic compounds for inhibition of inhibitors of apoptosis |
| 05/16/2013 | WO2013071010A1 PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF 4-PREGENEN-11ß-17-21-TRIOL-3,20-DIONE DERIVATIVES |
| 05/16/2013 | WO2013071009A1 4 - pregenen- 11ss - 17 - 21 -triol-3, 20 -dione derivatives for the treatment of ocular conditions |
| 05/16/2013 | WO2013071001A1 Treatment of ovarian cancer with benzylidenebenzohydrazides |
| 05/16/2013 | WO2013070998A1 TREATMENT OF OVARIAN CANCER WITH 2-AMINO-4H-NAPHTHO[1,2-b]PYRAN-3-CARBONITRILES |
| 05/16/2013 | WO2013070996A1 Method of treating a proliferative disease |
| 05/16/2013 | WO2013070961A1 Modulators of atp-binding cassette transporters |
| 05/16/2013 | WO2013070911A1 Compounds and methods for treating cystic fibrosis |
| 05/16/2013 | WO2013070910A1 Reducing transmission of sexually transmitted infections |
| 05/16/2013 | WO2013070903A1 Method of quantifying cancer treatment |
| 05/16/2013 | WO2013070890A1 Dual inhibitor of met and vegf for treating cancer |
| 05/16/2013 | WO2013070887A1 Substituted purine nucleosides, phosphoramidate and phosphordiamidate derivatives for treatment of viral infections |
| 05/16/2013 | WO2013070879A1 Methods for treating spinal cord injury with lpa receptor antagonists |
| 05/16/2013 | WO2013070861A1 Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions |
| 05/16/2013 | WO2013070852A2 Compounds and compositions used to epigenetically transform cells and methods related thereto |
| 05/16/2013 | WO2013070821A1 Methods and compositions for treating diseases, disorders or injury of the nervous system |
| 05/16/2013 | WO2013070763A1 Aptamer-loaded, biocompatible nanoconstructs for nuclear-targeted cancer therapy |
| 05/16/2013 | WO2013070688A1 Reprogramming urokinase into an antibody-recruiting anticancer agent |
| 05/16/2013 | WO2013070660A1 Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction |
| 05/16/2013 | WO2013070659A1 Modulators of opioid receptors and methods of use thereof |
| 05/16/2013 | WO2013070657A1 Modulators of the g protein-coupled mas receptor and the treatment of disorders related thereto |
| 05/16/2013 | WO2013070623A1 An extended release formulation of a direct thrombin inhibitor |
| 05/16/2013 | WO2013070620A1 Heterocyclic analogs of propargyl-linked inhibitors of dihydrofolate reductase |
| 05/16/2013 | WO2013070617A1 Compositions, dosage forms, and coadministration of an opioid agonist compound and an analgesic compound |
| 05/16/2013 | WO2013070606A1 Methods for treating inflammatory diseases and pharmaceutical combinations useful therefor |
| 05/16/2013 | WO2013070586A1 Small molecule modulators of prb inactivation |
| 05/16/2013 | WO2013070526A1 Methods for the treatment of skin neoplasms |
| 05/16/2013 | WO2013070471A1 Evaluation of presence of and vulnerability to atrial fibrillation and other indications using matrix metalloproteinase-based imaging |
| 05/16/2013 | WO2013070463A2 Treatment of blood lipid abnormalities and other conditions |
| 05/16/2013 | WO2013070460A1 Combination therapy for ovarian cancer |